

SUPPLEMENTARY MATERIAL

Disease Monitoring and Main Definitions

Donor total chimerism was assessed in whole blood by polymerase chain reaction for variable number tandem repeat polymorphisms at day +30 and +60 in all patients and according to clinical need thereafter. All patients underwent bone marrow examination at day +60 for marrow cellularity.

Neutrophil engraftment was defined as the first of three consecutive days with an absolute neutrophil count $\geq 0.5 \times 10^9/L$ and platelet engraftment was defined as a sustained and transfusion-independent platelet count $> 20 \times 10^9/L$ (1st of 3 days) without transfusion x 7 days.

Primary graft failure was defined as peripheral blood ANC $< 0.5 \times 10^9/L$ by day+28 after allo-HSCT in the absence of relapse, secondary graft failure was defined as loss of donor chimerism ($< 5\%$ donor cells), in whole blood, after initial engraftment and recurrent ANC $< 0.5 \times 10^9/L$.

Overall Survival was calculated from the date of the transplant to the date of death or last follow-up.

Supplementary Figure 1. Cumulative Incidence of Acute and chronic GVHD in all 58 Patients.

- A) Cumulative incidence of grade II-IV acute GVHD. B) Cumulative incidence of any grade of chronic GVHD.

